Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VYGR Stock Forecast 2026-2027
$4.05
Current Price
$244.69M
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VYGR Price Targets
+517.3%
To High Target of $25.00
+196.3%
To Median Target of $12.00
+97.5%
To Low Target of $8.00
VYGR Price Momentum
+7.7%
1 Week Change
+2.3%
1 Month Change
+27.8%
1 Year Change
+3.1%
Year-to-Date Change
-27.0%
From 52W High of $5.55
+52.8%
From 52W Low of $2.65
📊 TOP ANALYST CALLS
Did VYGR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Voyager is one of their latest high-conviction picks.
Latest VYGR Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, VYGR has a bullish consensus with a median price target of $12.00 (ranging from $8.00 to $25.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.05, the median forecast implies a 196.3% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 517.3% upside. Conversely, the most conservative target is provided by Yun Zhong at Wedbush, suggesting a 97.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VYGR Analyst Ratings
11
Buy
0
Hold
0
Sell
VYGR Price Target Range
Low
$8.00
Average
$12.00
High
$25.00
Current: $4.05
Latest VYGR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VYGR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 17, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $25.00 |
| Nov 12, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $25.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $30.00 |
| Aug 7, 2025 | Wedbush | Yun Zhong | Outperform | Maintains | $8.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Mar 13, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $12.00 |
| Mar 12, 2025 | Wedbush | Yun Zhong | Outperform | Reiterates | $N/A |
| Mar 12, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $N/A |
| Mar 12, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $10.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Jan 10, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Initiates | $5.73 |
| Dec 2, 2024 | Citigroup | Samantha Semenkow | Buy | Initiates | $12.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Nov 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $14.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Oct 16, 2024 | Leerink Partners | Lili Nsongo | Outperform | Initiates | $15.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $30.00 |
| Aug 7, 2024 | Wedbush | Laura Chico | Neutral | Maintains | $7.00 |
Voyager Therapeutics Inc. (VYGR) Competitors
The following stocks are similar to Voyager based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Voyager Therapeutics Inc. (VYGR) Financial Data
Voyager Therapeutics Inc. has a market capitalization of $244.69M with a P/E ratio of 6.1x. The company generates $40.37M in trailing twelve-month revenue with a -296.5% profit margin.
Revenue growth is +144.3% quarter-over-quarter, while maintaining an operating margin of -172.4% and return on equity of -48.3%.
Valuation Metrics
Market Cap
$244.69M
Enterprise Value
$76.07M
P/E Ratio
6.1x
PEG Ratio
-0.3x
Price/Sales
6.1x
Growth & Margins
Revenue Growth (YoY)
+144.3%
Gross Margin
N/A
Operating Margin
-172.4%
Net Margin
-296.5%
EPS Growth
+144.3%
Financial Health
Cash/Price Ratio
+81.4%
Current Ratio
7.6x
Debt/Equity
18.6x
ROE
-48.3%
ROA
-24.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Voyager Therapeutics Inc. (VYGR) Business Model
About Voyager Therapeutics Inc.
What They Do
Develops gene therapies for neurological diseases.
Business Model
The company focuses on developing innovative gene therapies aimed at severe neurological conditions with limited treatment options. Voyager Therapeutics generates revenue through partnerships and collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its proprietary therapies.
Additional Information
Voyager Therapeutics is headquartered in Cambridge, Massachusetts, and boasts a strong pipeline of preclinical and clinical-stage programs utilizing its advanced AAV capsid engineering technology, which enhances the targeting and expression of therapeutic genes within the central nervous system.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
172
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Country
United States
IPO Year
2015
Website
www.voyagertherapeutics.comVoyager Therapeutics Inc. (VYGR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +12.96% and -74.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Voyager Therapeutics reported Q1 2026 results, ending with $172M cash, sufficient until 2028. IND-enabling toxicology for VY1706 and NBIB-‘233 completed; clinical entry expected H2 2026.
Why It Matters
Positive clinical progress and a strong cash position suggest Voyager Therapeutics is well-funded for future developments, potentially increasing investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
VY1706, a gene therapy for Alzheimer's disease, showed promising pharmacology and safety in a 3-month GLP toxicology study in non-human primates.
Why It Matters
Positive results from VY1706's toxicology study suggest strong potential for Alzheimer's treatment, which could drive stock prices and investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Voyager Therapeutics holds a "Strong Buy" rating as it nears a key 2026 milestone with promising Alzheimer's data. The company has a solid cash position, funding through 2028, and potential $2.4B in milestones.
Why It Matters
Voyager Therapeutics shows strong growth potential with positive drug data and solid funding, indicating a promising future for investors amid Alzheimer's treatment advancements.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Voyager Therapeutics, Inc. (VYGR) presented at the Stifel 2026 Virtual CNS Forum, sharing insights on its developments in central nervous system therapies.
Why It Matters
Voyager Therapeutics' presentation at the Stifel 2026 Virtual CNS Forum signals potential advancements in their pipeline, impacting investor perceptions of future growth and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Voyager Therapeutics anticipates key clinical developments in H2 2026, including VY1706 and VY7523. The company ended 2025 with $202 million in cash, projected to last into 2028.
Why It Matters
The news indicates promising advancements in Alzheimer's treatments and a strong cash position, suggesting potential growth and stability for investors in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Voyager Therapeutics (VYGR) reported a quarterly loss of $0.46 per share, better than the expected loss of $0.54, and an improvement from a loss of $0.59 per share a year earlier.
Why It Matters
Voyager Therapeutics' smaller-than-expected quarterly loss suggests improving financial performance and may boost investor confidence, potentially impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About VYGR Stock
What is Voyager Therapeutics Inc.'s (VYGR) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Voyager Therapeutics Inc. (VYGR) has a median price target of $12.00. The highest price target is $25.00 and the lowest is $8.00.
Is VYGR stock a good investment in 2026?
According to current analyst ratings, VYGR has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VYGR stock?
Wall Street analysts predict VYGR stock could reach $12.00 in the next 12 months. This represents a 196.3% increase from the current price of $4.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Voyager Therapeutics Inc.'s business model?
The company focuses on developing innovative gene therapies aimed at severe neurological conditions with limited treatment options. Voyager Therapeutics generates revenue through partnerships and collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its proprietary therapies.
What is the highest forecasted price for VYGR Voyager Therapeutics Inc.?
The highest price target for VYGR is $25.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 517.3% increase from the current price of $4.05.
What is the lowest forecasted price for VYGR Voyager Therapeutics Inc.?
The lowest price target for VYGR is $8.00 from Yun Zhong at Wedbush, which represents a 97.5% increase from the current price of $4.05.
What is the overall VYGR consensus from analysts for Voyager Therapeutics Inc.?
The overall analyst consensus for VYGR is bullish. Out of 20 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are VYGR stock price projections?
Stock price projections, including those for Voyager Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 4:13 AM UTC